Skip to main content
. 2013 Oct 21;210(11):2223–2237. doi: 10.1084/jem.20131219

Figure 8.

Figure 8.

TNF blockade results in anti-tumor effects after anti-CD40/IL-2 therapy in aged mice. (A) Tumor survival in aged (12–15 mo) mice that received 3LL i.v. (day −3), followed by low-dose anti-CD40/IL-2 with etanercept (n = 8–10) or hIgG (n = 6) or PBS/rIgG (n = 6). (B and C) Number of CD3+ CD8+ T cells in the spleen after 9 d of treatment in aged (12 mo) C57BL/6 mice (B) and their percent lysis of total spleen cells against P815 tumors at different effector to target ratio (C), n = 3. Survival analysis was plotted according to the Kaplan-Meier method, and statistical differences were determined with the log-rank test. ***, P < 0.001, IT/hIgG versus IT/etanercept; *, P < 0.05, IT/Etanercept versus rIgG/PBS; *, P < 0.01, rIgG/PBS versus Low IT/hIgG. Survival curve of one of two independent experiments is represented. For B and C, values represent the mean ± SEM of one of two independent experiments tested by one-way or two-way ANOVA, respectively. ***, P < 0.001; **, P < 0.01; *, P < 0.05 compared with control group. A–C are representative of three independent experiments.